Cited by 148Cancer Treatment and PharmacologyChemotherapy-related skin toxicityPain Mechanisms and Treatments

Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine

Open access
Boyette-Davis, Jessica A., Cata, Juan P., Driver, Larry C., Novy, Diane M., Bruel, Brian M., Mooring, Deidre L., Wendelschafer-Crabb, Gwen, Kennedy, William R. +1 more·2013·Cancer Chemotherapy and Pharmacology

Abstract

Purpose Chemoneuropathy remains a painful, burdensome complication of cancer treatment for patients receiving a range of chemotherapeutics, yet the cause and persistence of this condition are not fully documented. This study was designed to quantify the longevity of and contributions to neuropathy following treatment with the plant alkaloids paclitaxel and vincristine.Methods Quantitative sensory testing was conducted approximately 18 months apart on 14 patients, seven of which had been treated with paclitaxel and seven with vincristine and compared to data from 18 healthy control subjects. In addition, skin biopsies were obtained to investigate changes in the density of Meissner's corpuscles and epidermal nerve fibers (ENFs), the loss of which is thought to contribute to multiple forms of neuropathy.Results Impairments in motor skills, as measured by a grooved peg-board, were found. Deficits in touch detection were observed using von Frey monofilaments, as were changes in sharpness detection using a weighted needle device. Using a Peltier device, warmth and heat detection were impaired. These deficits were consistent across time. Remarkably, the average length of time patients reported painful neuropathy was over four and a half years. Skin biopsies were found to be deficient in Meissner's corpuscles and ENFs.Conclusions The combination of widespread deficits in sensory testing and decreases in skin innervation for cancer patients receiving paclitaxel or vincristine document a persistent polyneuropathy which severely impacts these patients. Decreases in Meissner's corpuscles and ENFs indicate a possible mechanism for the neuropathy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00280-012-2047-z

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Boyette-Davis, J. A., Cata, J. P., Driver, L. C., Novy, D. M., Bruel, B. M., Mooring, D. L., Wendelschafer-Crabb, G., Kennedy, W. R., & Dougherty, P. M.
Affiliations
  • York College of Pennsylvania (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Minnesota (US)
Corresponding author
Dougherty, Patrick M.
Venue
Cancer Chemotherapy and Pharmacology
Published
2012-12-11
Volume
71
Issue
3
Pages
619-626
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W1981358093
Cited by
148
References
29
Citations by year
2026: 9 · 2025: 9 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 10 · 2020: 13 · 2019: 10 · 2018: 14 · 2017: 14 · 2016: 11 · 2015: 13 · 2014: 8 · 2013: 2
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (CA124787., P01CA124787, P30CA016672)
  • National Institute of Neurological Disorders and Stroke (NS 046606, R01NS046606)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
Keywords
paclitaxel, vincristine, plant alkaloids, polyneuropathy, Meissner corpuscles, epidermal nerve fibers, skin innervation, quantitative sensory testing, chemotherapy side effects, sensory impairment
MeSH terms
Aged, Antineoplastic Agents, Phytogenic, Biopsy, Female, Humans, Male, Mechanoreceptors, Middle Aged, Motor Skills, Nerve Fibers, Pain, Pain Measurement, Peripheral Nervous System Diseases, Physical Stimulation, Pilot Projects, Sensory Thresholds, Skin, Thermosensing, Touch, Vincristine, Paclitaxel, Neurotoxicity Syndromes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review